1. Home
  2. TCRX vs LSE Comparison

TCRX vs LSE Comparison

Compare TCRX & LSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCRX
  • LSE
  • Stock Information
  • Founded
  • TCRX 2018
  • LSE 2007
  • Country
  • TCRX United States
  • LSE China
  • Employees
  • TCRX N/A
  • LSE N/A
  • Industry
  • TCRX Biotechnology: Pharmaceutical Preparations
  • LSE Metal Fabrications
  • Sector
  • TCRX Health Care
  • LSE Industrials
  • Exchange
  • TCRX Nasdaq
  • LSE Nasdaq
  • Market Cap
  • TCRX 91.7M
  • LSE 91.8M
  • IPO Year
  • TCRX 2021
  • LSE 2024
  • Fundamental
  • Price
  • TCRX $1.91
  • LSE $5.25
  • Analyst Decision
  • TCRX Strong Buy
  • LSE
  • Analyst Count
  • TCRX 5
  • LSE 0
  • Target Price
  • TCRX $9.40
  • LSE N/A
  • AVG Volume (30 Days)
  • TCRX 208.8K
  • LSE 7.0K
  • Earning Date
  • TCRX 08-12-2025
  • LSE 01-01-0001
  • Dividend Yield
  • TCRX N/A
  • LSE N/A
  • EPS Growth
  • TCRX N/A
  • LSE N/A
  • EPS
  • TCRX N/A
  • LSE 0.52
  • Revenue
  • TCRX $6,961,000.00
  • LSE $69,073,374.00
  • Revenue This Year
  • TCRX $255.18
  • LSE N/A
  • Revenue Next Year
  • TCRX N/A
  • LSE N/A
  • P/E Ratio
  • TCRX N/A
  • LSE $10.05
  • Revenue Growth
  • TCRX N/A
  • LSE N/A
  • 52 Week Low
  • TCRX $1.02
  • LSE $3.76
  • 52 Week High
  • TCRX $6.23
  • LSE $14.99
  • Technical
  • Relative Strength Index (RSI)
  • TCRX 59.09
  • LSE 42.66
  • Support Level
  • TCRX $1.73
  • LSE $5.20
  • Resistance Level
  • TCRX $1.95
  • LSE $5.59
  • Average True Range (ATR)
  • TCRX 0.12
  • LSE 0.25
  • MACD
  • TCRX 0.01
  • LSE 0.00
  • Stochastic Oscillator
  • TCRX 84.85
  • LSE 22.41

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About LSE Leishen Energy Holding Co. Ltd. Ordinary Shares

Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment; oil and gas engineering technical services; new energy production and operation; and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment which supplies various equipments, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.

Share on Social Networks: